Hutchmed (HCM) said late Tuesday it completed patient enrollment in a phase 3 study of Orpathys and Tagrisso as a first-line combination treatment of a certain type of non-small cell lung cancer.

The treatment targets patients whose tumors harbor epidermal growth factor receptor mutation and MET overexpression. The company said the study will evaluate the efficacy and safety of the combination, compared with Tagrisso alone, a standard-of-care treatment option.

The trial's primary endpoint is progression-free survival, while other endpoints include overall survival, objective response rate, and duration of response.

Hutchmed expects topline results by H2 2026, with potential favorable results to pave the way for a supplementary new drug application submission to China's National Medical Products Administration, the company said.